PMID- 34385029
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20220124
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 99
DP  - 2021 Oct
TI  - Prognostic nomogram incorporating cytokines for overall survival in patients with 
      newly diagnosed multiple myeloma.
PG  - 108016
LID - S1567-5769(21)00652-4 [pii]
LID - 10.1016/j.intimp.2021.108016 [doi]
AB  - OBJECTIVE: The purpose of this study was to explore the relationship between 
      pretreatment cytokine status and overall survival and establish a prognostic 
      nomogram incorporating cytokines in newly diagnosed multiple myeloma (NDMM) 
      patients. METHODS: A total of 121 patients with NDMM from the Wuhan Union 
      Hospital were included in our study. Patient serum levels of cytokines, including 
      macrophage inflammatory protein 1 alpha (MIP-1alpha), migration inhibitory factor 
      (MIF), tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor-alpha 
      (VEGF-alpha), monocyte chemoattractant protein-1 (MCP-1) and soluble interleukins 
      IL-17A, IL-6, IL-21 and IL-10 were assessed before treatment. Based on the 
      results of the multivariate Cox proportional hazards model, we developed a 
      prognostic nomogram. We used the concordance index (C-index) and a calibration 
      curve to measure the predictive performance of the nomogram. RESULTS: Three 
      important variables (lactate dehydrogenase, MIP-1alpha and creatinine) were 
      incorporated in the nomogram using multivariate Cox analysis. The 3-year overall 
      survival (OS) rate and progression-free survival (PFS) rate were 83.8% and 21.8% 
      in the low-risk group of the nomogram and 17.4% and 8.4% in the high-risk group, 
      respectively. The C-index of the nomogram for OS prediction was 0.80 (95% CI: 
      0.68-0.92), showing superiority over the predictive power of the Durie-Salmon 
      staging system (C-index = 0.58; 95% CI: 0.49-0.67), International Staging System 
      (C-index = 0.70; 95% CI: 0.61-0.79) and Revised-International Staging System 
      (C-index = 0.71; 95% CI: 0.63-0.80). The calibration curve showed that the 
      nomogram accurately predicted the 1-year, 2-year and 3-year OS of NDMM patients. 
      CONCLUSION: The established nomogram provides accurate and individualized OS risk 
      estimation for NDMM patients.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - Cheng, Qianwen
AU  - Cheng Q
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Zhao, Fei
AU  - Zhao F
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Zhang, Yuyang
AU  - Zhang Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Cai, Li
AU  - Cai L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Qiao, Bing
AU  - Qiao B
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China.
FAU - Hu, Yu
AU  - Hu Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China; Collaborative 
      Innovation Center of Hematology, Huazhong University of Science and Technology, 
      Wuhan 430022, Hubei, China. Electronic address: dr_huyu@126.com.
FAU - Sun, Chunyan
AU  - Sun C
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, Hubei, China; Collaborative 
      Innovation Center of Hematology, Huazhong University of Science and Technology, 
      Wuhan 430022, Hubei, China. Electronic address: suncy0618@163.com.
LA  - eng
PT  - Journal Article
DEP - 20210809
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cytokines)
RN  - 0 (MAPKAP1 protein, human)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/blood
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Creatinine/blood
MH  - Cytokines/*blood
MH  - Female
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/diagnosis/immunology/*mortality
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - *Nomograms
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - Cytokines
OT  - Newly diagnosed multiple myeloma
OT  - Nomogram
OT  - Prognosis
EDAT- 2021/08/14 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/08/13 06:04
PHST- 2021/03/10 00:00 [received]
PHST- 2021/07/20 00:00 [revised]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/08/13 06:04 [entrez]
AID - S1567-5769(21)00652-4 [pii]
AID - 10.1016/j.intimp.2021.108016 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Oct;99:108016. doi: 10.1016/j.intimp.2021.108016. Epub 
      2021 Aug 9.